Sionna Therapeutics, Inc. Common Stock (SION) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has a cash flow conversion efficiency ratio of -0.054x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.63 Million) by net assets ($306.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SION market cap overview for the company's overall valuation and market capitalisation.
Sionna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sionna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Sionna Therapeutics, Inc. Common Stock (SION) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yuen Foong Yu Consumer Prod
TW:6790
|
0.071x |
|
Everyday Network
SHE:300295
|
0.074x |
|
BLD Plantation Bhd
KLSE:5069
|
-0.051x |
|
MM Forgings Limited
NSE:MMFL
|
0.196x |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
0.030x |
|
Ve Wong Corp
TW:1203
|
0.048x |
|
Gérard Perrier Industrie S.A.
PA:PERR
|
0.163x |
|
Lands’ End Inc
NASDAQ:LE
|
-0.148x |
Annual Cash Flow Conversion Efficiency for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. View latest Sionna Therapeutics, Inc. Common Stock stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $306.83 Million | $-66.30 Million | -0.216x | -167.01% |
| 2024-12-31 | $-163.71 Million | $-52.79 Million | 0.322x | -15.23% |
| 2023-12-31 | $-114.88 Million | $-43.70 Million | 0.380x | -26.26% |
| 2022-12-31 | $-69.92 Million | $-36.07 Million | 0.516x | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more